Reduced Folate Composition Mitigating Methotrexate Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Prolonged use of dihydrofolate reductase inhibitors, such as methotrexate, leads to folate deficiency and adverse effects like gastrointestinal, mucocutaneous, and hematological issues, as well as liver toxicity, due to inhibition of the DHFR enzyme, which existing treatments fail to comprehensively address, especially in outpatients without venous access for folate supplementation.
Innovation Solution
A pharmaceutical composition containing a reduced form of folate, standardized milk thistle extract (Silybum marianum), vitamin B complex, essential and non-essential amino acids, and pharmaceutically acceptable excipients, administered orally to mitigate adverse effects by providing active folate without relying on DHFR and protecting the liver.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DHFR inhibitors are used to treat diseases, then therapeutic effect is improved, but folate deficiency and adverse effects occur
Solution Approach 1:
The patent introduces a combination of intermediaries (reduced folate, silymarin, vitamin B12, and other cofactors) that mediate between the DHFR inhibitor therapy and the body's folate metabolism. These intermediaries work together to counteract the inhibitor's effects while preserving therapeutic benefits, with reduced folate serving as the primary mediator to replenish folate pools and silymarin protecting against hepatotoxicity.
Solution Approach 2:
The patent employs a composite formulation combining multiple substances (reduced folate, silymarin, vitamin B12, L-methionine, L-serine, L-glycine, and other cofactors) that work synergistically. Each component addresses specific aspects of DHFR inhibitor toxicity, creating a comprehensive protective effect that none of the individual components could achieve alone.
2Reliability
If parenteral calcium folinate supplementation is used, then folate deficiency is prevented, but it is not practical for outpatients without venous access
Solution Approach 1:
The patent replaces the complex, invasive parenteral calcium folinate administration with simple oral tablets containing reduced folate and other cofactors. This disposable oral formulation eliminates the need for venous access devices and hospital infrastructure, making folate supplementation practical for long-term outpatient use while maintaining effectiveness.
Solution Approach 2:
The patent uses reduced folate as an intermediary substance that can be orally administered and directly absorbed, bypassing the need for parenteral route. This intermediary form of folate, combined with other cofactors, serves as a practical mediator that delivers the necessary folate supplementation to outpatients without requiring venous access.
3Ease of operation
If oral folic acid supplementation is used, then it is easy to administer, but it is not effective because DHFR is inhibited
Solution Approach 1:
The patent changes the chemical parameter of the folate supplement from oxidized folic acid to reduced folate forms. This parameter change allows the supplement to be effective despite DHFR inhibition, as the reduced forms can directly donate methyl groups without requiring DHFR-mediated reduction. The combination with vitamin B12 and other cofactors further enhances this effectiveness.
Solution Approach 2:
The patent creates a composite oral supplement containing reduced folate, vitamin B12, L-methionine, L-serine, L-glycine, and other cofactors. This composite formulation works synergistically to bypass the blocked DHFR pathway, with each component contributing to restoring one-carbon metabolism and preventing folate deficiency despite the inhibitor's presence.
4Duration of action of stationary object
If MTX is used for long-term treatment, then chronic diseases are controlled, but liver toxicity increases
Solution Approach 1:
The patent applies silymarin, a compound derived from milk thistle, which has demonstrated hepatoprotective properties. Silymarin converts the harmful effect of MTX-induced liver toxicity into a beneficial protective effect by reducing oxidative stress, preventing lipid peroxidation, and protecting hepatocyte membranes, thereby enabling long-term MTX treatment with reduced liver damage.
Solution Approach 2:
The patent incorporates silymarin into a composite formulation with reduced folate and other cofactors. This composite approach addresses both the folate deficiency and liver toxicity aspects of long-term MTX treatment simultaneously, with each component contributing to overall hepatoprotection and metabolic support during chronic therapy.
Data Source
AI summary
The present invention relates to pharmaceutical compositions containing a combination of reduced forms of folate, liver protectors, vitamins, and essential or non-essential amino acids, useful in preventing the adverse effects associated with prolonged use of dihydrofolate reductase inhibitors.